This patent covers ways of generating human embryonic stem cells. Some of the claims have priority to the WARF patents. Essentially the patent teaches that embryonic stem cells can be generated by culture of primordial germ cells in agents such as bFGF, SF and LIF. The...
This patent covers certain types of embryonic stem cells and their use for screening. Note that this patent has priority to the WARF patents...
This is one of the early embryonic stem cell patents. In this one embryonic stem cells are maintained in LIF, stem cell factor, and fibroblast growth factor. It is interesting to analyze this patent in light of the WARF patents because there is some very interesting similarities to the approaches.
This patent covers a type of stem cell that gives rise to numerous neural lineages. The stem cell is useful for administration after differentiation, administration in an undifferentiated state, as well as administration after gene transfection. This stem cell is purified from the fetal neural crest.
This patent covers neural stem cells that are transfected with various oncogenes so as to make them immortal. These cells would be highly beneficial for cell therapy of neurodegenerative diseases, if the safety issue of potential oncogenesis can be overcome.
This patent covers the CD34+, HLA-DR negative, c-kit positive, hematopoietic stem cell.
This patent covers a type of neural stem cell that is derived from the neural crest and expresses a specific phenotypic profile that allows not only for isolation, but also in vitro and in vivo identification.
This stem cell type is capable of differentiating into neurons similar to those found in the peripheral nervious system, as well as microglia.
The cell has a phenotype of
LNGFR expressing neural stem cells are patented. The use of these cells for targets of gene transfection, and subsequent administration of the transfected stem cells for therapeutic benefit is disclosed.
This patent covers the modification of cells to make them "universal donors" and thus not be rejected by the immune system. Not only is it next to impossible to completely inhibit expression of all immunogenic MHC molecules, but even if this is accomplished, the influence of the NK cells which kill tissue not expressing MHC must also be...
This patent provides a new type of stem cell that is similar to the mesenchymal stem cells covered by Osiris. It appears that the stem cells disclosed in this patent are derived from muscle cells. If these cells are mesenchymal or express the markers SH2-4 covered by Osiris, this could be an interesting patent to watch out for.